Projects per year
Fingerprint
Dive into the research topics where Gil Awada is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
Research output
-
Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)
Awada, G., Dirven, I., Schwarze, J. K., Tijtgat, J., Fasolino, G., Kockx, M. & Neyns, B., 15 Feb 2024, In: JCO precision oncology. 8, p. 1-10 10 p., PO.23.00493.Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (Scopus)25 Downloads (Pure) -
Analysis of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: a case series
Dirven, I., Hautman, R. M. A., Awada, G., Tijtgat, J., Vounckx, M., Vanbinst, A. & Neyns, B., 21 Apr 2023, (Unpublished).Research output: Unpublished contribution to conference › Other
-
Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study
Fasolino, G., Awada, G., Moschetta, L., Koulalis, J. S., Neyns, B., Verhelst, B., Van Elderen, P., Nelis, P., de Lichtbuer, P. C., Cools, W. & Ten Tusscher, M., 3 Feb 2023, In: Journal of clinical medicine. 12, 3, 10 p., 1214.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)12 Downloads (Pure) -
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors
Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Kruse, V. & Neyns, B., 1 Jun 2022, In: Melanoma Research. 32, 3, p. 183-191 9 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile10 Citations (Scopus)33 Downloads (Pure) -
Anti-PD-1: When to Stop Treatment
Jansen, Y., van der Veldt, A. A. M., Awada, G. & Neyns, B., Jul 2022, In: Current oncology reports. 24, 7, p. 905-915 11 p.Research output: Contribution to journal › Scientific review › peer-review
11 Citations (Scopus)3 Downloads (Pure)
Prizes
-
Best Poster Award
Awada, Gil (Recipient), Özdemir, Ibrahim (Recipient), Schwarze, Julia Katharina (Recipient), Daeninck, Emma (Recipient), Gondry, Odrade (Recipient), Jansen, Y. (Recipient), Seremet, T. (Recipient), Keyaerts, Marleen (Recipient), Everaert, Hendrik (Recipient) & Neyns, Bart (Recipient), 15 Dec 2018
Prize: Prize (including medals and awards)
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor) & Bart Neyns (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
Prognostic value of 0-(2-[18F]-fluoroethyl)-L-tyrosine PET in patients with recurrent glioblastoma.
Wietse Geens (Speaker), Stephanie Du Four (Contributor), S VAN LAERE (Contributor), Julia Katharina Schwarze (Contributor), Gil Awada (Contributor), Michaël Bruneau (Contributor), Jens Tijtgat (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): a multi-cohort adaptive phase I clinical trial
Julia Katharina Schwarze (Speaker), Wietse Geens (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), Anne-Marie Van Binst (Contributor), Hendrik Everaert (Contributor), Laura Seynaeve (Contributor), Alex Michotte (Contributor), Michaël Bruneau (Contributor), I VAN RIET (Contributor), Sandra Tuyaerts (Contributor), Johnny Duerinck (Contributor) & Bart Neyns (Contributor)
16 Sep 2021 → 21 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor) & Bart Neyns (Contributor)
17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
Thesis
-
Expanding the application of targeted therapies and immune checkpoint inhibitors in advanced melanoma and recurrent glioblastoma
Author: Awada, G., Neyns, B., Hes, F. J., Flaherty, K., Del Marmol, V., Engels, B., De Haar-Holleman, A. & Schots, R., 18 Jun 2021Supervisor: Neyns, B. (Promotor), Flaherty, K. (External person) (Jury), Del Marmol, V. (External person) (Jury), Hes, F. J. (Jury), Engels, B. (Jury), De Haar-Holleman, A. (Jury) & Schots, H. (Jury)
Student thesis: Doctoral Thesis